Skip to main
INFU

InfuSystem Hlds (INFU) Stock Forecast & Price Target

InfuSystem Hlds (INFU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

InfuSystems Holdings Inc. has demonstrated strong financial performance, with core oncology business achieving record quarterly revenue and a significant new contract with a major hospital system expected to enhance patient volumes in the upcoming quarter. The gross profit margin improved by 370 basis points to 55.2%, driven by strategic revenue mix optimization and normalized pump disposal costs, which supports sustainable profitability. Additionally, the year-to-date net operating cash flow reached $17.3 million, reflecting a 38% increase attributed to enhanced earnings and effective working capital management, positioning the company for future growth as auxiliary services in Wound Care and Pain Management gain traction.

Bears say

InfuSystems Holdings Inc has encountered a deterioration in gross margins, predominantly due to challenges within its lower-margin Device Solutions division, alongside increasing operational costs. Economic uncertainties have exacerbated the situation by prompting customer destocking, leading to diminished demand and reduced sales volumes, which have further exerted downward pressure on margins. The projected revenue for Fiscal Year 2026 reflects a stagnant forecast of $143.6 million, marking a decrease of $9.5 million compared to prior estimates, as various factors such as competitive headwinds and margin compression pose significant risks to the company's financial performance.

InfuSystem Hlds (INFU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InfuSystem Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InfuSystem Hlds (INFU) Forecast

Analysts have given InfuSystem Hlds (INFU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, InfuSystem Hlds (INFU) has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InfuSystem Hlds (INFU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.